IDEAYA Biosciences Inc (IDYA) News & EventsIDYANews & EventsIDEAYA Biosciences Inc

Ideaya Enters Clinical Collaboration with Genentech

Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Genentech, a member of Roche (RHHBY), to evaluate the efficacy and safety of IDE892, its investigational MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035, Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma harboring both an MTAP-deletion and a KRAS G12D mutation. Genentech will sponsor the clinical combination study, and Ideaya will supply IDE892. Under the clinical collaboration, Ideaya and Genentech each retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies. There will be joint governance to oversee the clinical supply collaboration.

Ideaya Biosciences Q2 Revenue $8.86M Beats Expectations

Reports Q2 revenue $8.86M, consensus $7.45M. "This quarter marked another successful step forward in our mission to deliver new, potentially best-in-class precision therapies for people with cancer. We presented the positive topline results at ASCO from our registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic uveal melanoma while continuing to advance our NDA submission and pre-commercial activities to support a possible commercial launch. Additionally, our clinical pipeline is poised to deliver several key updates throughout the remainder of 2026, including updated data from IDE849, our DLL3 TOP1 ADC, in SCLC and NEC and clinical progress in MTAP-deleted cancers with IDE892, our PRMT5 inhibitor, as both a monotherapy and in combination with IDE397, our proprietary MAT2A inhibitor, and RG6505, Roche's Phase 1 pan-RAS inhibitor in NSCLC and PDAC, respectively. With over $1.2 billion in cash following our successful financing in June, IDEAYA is well-positioned to continue advancing our precision medicine pipeline through multiple key data updates," said Yujiro S. Hata, President and Chief Executive Officer of Ideaya Biosciences.

Ideaya Biosciences Initiates IDE892 Monotherapy Expansion Trial

Ideaya Biosciences announced that initiation of Part 2 monotherapy expansion has been achieved in its Phase 1/2 clinical trial evaluating IDE892, a methylthioadenosine-cooperative inhibitor of PRMT5, in MTAP-deleted solid tumors, with a focus on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma. IDE892 Phase 1/2 monotherapy expansion has been initiated at projected efficacious target human exposures where 24-hours target EC90 coverage have been achieved. The IDE892 maximum tolerated dose has not yet been reached in the ongoing dose escalation.